GW Pharmaceuticals
Most Recent
Could Marijuana Legalization Help Texas Recover Its Losses?
Texas has suffered huge economic losses. Many industry experts think that marijuana legalization could be a good option to revive the state’s economy.
Marijuana: Banking Access Included in Coronavirus Relief Bill
Marijuana companies in the US have been struggling to get financial and banking access. Cannabis still isn’t legal at the federal level.
New Cannabis Store Opens before Green Thumb’s Q1 Earnings
Green Thumb Industries (OTCMKTS:GTBIF) will likely report its results for the first quarter of fiscal 2020 on May 14 after the market closes.
GW Pharmaceuticals Stock Rises on Higher Epidiolex Sales
On Monday, GW Pharmaceuticals reported its first-quarter earnings. The company beat analysts’ revenue, EBITDA, and EPS expectations.
Analysts Cut GW Pharmaceuticals’s Target Price after Q4 Earnings
On Tuesday, GW Pharmaceuticals reported its fourth-quarter earnings. The company reported revenue of $109.1 million, which beat analysts’ expectations.
Analyzing GW Pharmaceuticals’ Q4 Earnings and Outlook
On Tuesday, GW Pharmaceuticals reported its fourth-quarter earnings after the market closed. For the quarter, the company reported revenue of $109.1 million.
GW Pharmaceuticals Provides Preliminary Sales Update
On January 12, GW Pharmaceuticals announced its preliminary unaudited product sales report for the fourth quarter and 2019.
Is GW Pharmaceuticals a Good Bet?
Analysts expect GW Pharmaceuticals to become profitable in 2020. They expect the company’s EBITDA to be $42.8 million in 2020.
Is GW Pharmaceuticals a Good Buy in December 2019?
GW Pharmaceuticals (GWPH) is a leading player in cannabinoid medicines. The company offers the first FDA-approved plant-derived cannabinoid medicine.
What’s the Market Potential for CBD?
The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?
ACB Focuses on Medical Marijuana Opportunities
Aurora Cannabis’ (ACB) is receiving a lot of flak from analysts and investors. This happened after its disappointing first-quarter performance.
NHS Approves Cannabis Medicines: Market Impact
On November 11, the NHS (National Health Service) approved two cannabis-based medicines, Epidyolex and Sativex, for use in the United Kingdom.
Analyst Price Target GW Pharmaceuticals: Analysts’ Ratings, Price Target
GW Pharmaceuticals (GWPH) recently reported its QA3 results. Although its financials beat estimates, the company’s stock has fallen 18% since then.
What to Expect from IIPR’s Earnings for Q3
Innovative Industrial Properties (IIPR) is scheduled to release its Q3 earnings results on November 6. Find out what cannabis investors can expect.
Cannabis New Gallup Poll on Marijuana Legalization Support
A recent Gallup poll data found that nearly 66% of Americans support making cannabis legal. However, this figure was the same as in 2018. This suggests a standstill in the rise in support of cannabis legalization. Moreover, nine states will be voting in 2020 on measures to allow cannabis for recreational or medical use. The […]
Cannabis Stocks: What Happens in a Recession?
As market analysts increasingly predict an upcoming global recession, we take a look at the impact of a recession on cannabis stocks.
GW Pharmaceuticals: Target Price and Valuation Update
Thirteen analysts are covering GW Pharmaceuticals in October. Nine covered the stock in October 2018. The consensus target price for the stock is $226.85.
UK Approves Another Medicinal Cannabis Product
GW Pharmaceuticals has announced the European Commission’s approval of EPIDYOLEX. This will mark its entry into all European countries, including the UK.
Medical Cannabis: A Hot Topic at Events Across the World
These days, experts are discussing the pros and cons of medical cannabis at multiple conferences and summits around the world.
How Analysts View Cresco Labs before Its Q1 Release
Cresco Labs (CRLBF) is slated to release its first-quarter earnings on May 29.
Analyzing Charlotte’s Web Holdings’ Q1 Earnings Estimates
Charlotte’s Web Holdings (CWBHF) is scheduled to release its first-quarter earnings today and hold its earnings conference call tomorrow.
Comparing GW Pharmaceuticals’ Returns to Peers
GW Pharmaceuticals has received a “strong buy” rating from four analysts, while eight have rated it as a “buy” or some equivalent.
Ups and Downs in the Cannabis Space Last Week
The cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively.
Why Did Cannabis Stocks Fall on April 15?
Cannabis stocks were broadly in the red on April 15. Charlotte’s Web Holdings (CWBHF) saw a negative price action of 5.8%.
Green Growth Brands Ended in the Red Last Week
Green Growth Brands fell 1.6% and closed at $4.33 for the week ending February 8—marginally above the 20-day moving average price.
Analyzing CARA, INSY, and GWPH’s Earnings Trends
GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017.
CARA, INSY, and GWPH: Analysts’ Recommendations in January
On January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close.
Which Cannabis Stocks Were in the Green on January 24?
On January 24, Cannabis Strategic Ventures stock closed at $1.69—an ~8.33% rise compared to its closing price of $203.66 on January 23.
Cara Therapeutics: Earnings Trends and Recent Developments
In the first nine months of 2018, Cara Therapeutics (CARA) reported a net income and EPS of -$53.4 million and -$1.54, respectively.
Cara Therapeutics: A Financial Overview in January
In the first nine months of 2018, Cara Therapeutics (CARA) generated revenues of $7.9 million.
Cara Therapeutics Has Risen ~18% in January
Cara Therapeutics’ (CARA) stock price reached $15.35 on January 18—compared to $13.00 when the market closed on December 31.
How Is INSYS Therapeutics Financially Positioned in January?
In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.
Cannabis Stock INSYS Therapeutics Has Risen 28% in January
On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of markets on December 31.
Here Are Some of GW Pharmaceuticals’ Key Growth Drivers
GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results.
How GW Pharmaceuticals’ Earnings Are Trending
In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively.
A Look into GW Pharmaceuticals’ Revenue Trends
In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.
GW Pharmaceuticals Has Already Soared 23% in January
GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products.
GW Pharmaceuticals’ European Launch and Payer Access for Epidiolex
According to GW’s fiscal 2018 fourth-quarter earnings conference call, it’s planning to launch Epidiolex in five major European markets in 2019.
GW Pharmaceuticals Focuses on Epidiolex’s US Commercial Launch
On September 5, the US Department of Justice and the DEA issued a press release announcing the rescheduling of Epidiolex into Schedule V of the Controlled Substances Act.
Epidiolex Launch Expected to Push Up GW’s Operating Expenses
Analysts expect GW Pharmaceuticals to report SG&A (selling, general, and administrative) expenses of $179.14 million in 2019.
GW Pharmaceuticals Is Expected to Turn Profitable in 2020
In fiscal 2018, which ended on September 30, GW Pharmaceuticals (GWPH) reported total revenue of $12.74 million.
Revenue Spike Expected for GW Pharmaceuticals in 2019
On its fiscal 2018 fourth-quarter earnings conference call, GW Pharmaceuticals (GWPH) announced the change of the end of its fiscal year.
What’s Auxly Cannabis’ MidStream Strategy in 2018?
On August 31, Auxly Cannabis announced the completion of the acquisition of KGK Science for a total consideration of $12.3 million.
Trulieve to Announce Q3 Earnings on November 19!
Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET.
Curaleaf Opens Medical Marijuana Dispensary in Tallahassee
On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary.
WeedMD Secures Cannabis Sales License from Health Canada
On November 13, WeedMD announced that Health Canada approved its cannabis sales license for cannabis cultivated at its greenhouse in Ontario.
What to Expect from Cannabis Player Curaleaf’s Q3 Earnings
A look at Curaleaf Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf Holdings has announced that it will release its third-quarter earnings results on November 26. We’ll discuss analysts’ estimates for its EPS and revenue in this article. The chart above compares Curaleaf Holdings’ revenues since the third […]
How Marijuana-Focused Biotech Companies Have Performed in 2018
In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.
GW Pharmaceuticals: Recommendations and Market Capitalization
Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.
Marijuana-Focused Biotech Companies in Q3: Are They Performing?
In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.
